Isabel Arrillaga-Romany, MD
Neurology · Boston, MANPI 1972762326
Payments from drug & device makers
Across 346 payments — averaging $23,811 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Bioinnovation$4.9M
- GSK$2.2M
- Servier Pharmaceuticals LLC$747K
- Otsuka Pharmaceutical Co., Ltd.$148K
- Jazz Pharmaceuticals Inc.$93K
- Merck$83K
- plus $80K from 1 others
Across 8 payments — averaging $609.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$5K
What the payments were for
- Speaking & faculty fees$2,040100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Bioinnovation | 241 | $4,908,102 |
| GSK | 14 | $2,179,319 |
| Servier Pharmaceuticals LLC | 25 | $746,603 |
| Otsuka Pharmaceutical Co., Ltd. | 8 | $148,249 |
| Jazz Pharmaceuticals Inc. | 29 | $93,101 |
| Merck | 2 | $82,800 |
| Agios Pharmaceuticals, Inc. | 27 | $80,339 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TIBSOVO$2,040
How this compares
$8,238,512 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GleostineLomustine | 18 | $16,895 |
| Levetiracetam ErLevetiracetam | 20 | $672 |
| Dexamethasone | 14 | $281 |
| Levetiracetam | 13 | $258 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
- Luis Gonzalez CastroBoston$5.7M
- Tanuja ChitnisBoston$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.